MBX Biosciences, Inc. Common Stock (MBX) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 4 Buy.
The consensus price target is $55.33 (low: $18.00, high: $88.00), representing an upside of 68.6% from the current price $32.81.
Analysts estimate Earnings Per Share (EPS) of $-11.52 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2025: actual $-2.38 vs est $-2.50 (beat +4.7%). Analyst accuracy: 95%.
MBX Stock — 12-Month Price Forecast
$55.33
▲ +68.64% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for MBX Biosciences, Inc. Common Stock, the average price target is $55.33, with a high forecast of $88.00, and a low forecast of $18.00.
The average price target represents a +68.64% change from the last price of $32.81.
Highest Price Target
$88.00
Average Price Target
$55.33
Lowest Price Target
$18.00
MBX Analyst Ratings
Buy
Based on 4 analysts giving stock ratings to MBX Biosciences, Inc. Common Stock in the past 3 months
EPS Estimates — MBX
95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.00
vs Est –$11.52
▲ 0.0% off
2025
Actual –$2.38
vs Est –$2.50
▲ 4.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — MBX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
